BioMarin Pharmaceutical Inc., a California-based biotech firm, is committed to developing and delivering innovative therapies to people with serious and life-threatening rare diseases and medical conditions. The company's impressive portfolio of commercial products includes Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme. Each product targets a specific issue, such as lysosomal storage disorders, inherited metabolic diseases, and ceroid lipofuscinosis type 2, also known as Batten disease. BioMarin is also engaged in developing Roctavian, an adeno associated virus vector, for the treatment of hemophilia A, BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema, and BMN 255 for treating primary hyperoxaluria. The company serves various entities, including specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and other parts of the world. BioMarin has established several license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Since its inception in 1996, BioMarin has positioned itself at the forefront of the biotech industry, consistently pushing boundaries and developing groundbreaking therapies that have the potential to change the lives of those in need.
BioMarin Pharmaceutical's ticker is BMRN
The company's shares trade on the NASDAQ stock exchange
They are based in San Rafael, California
There are 1001-5000 employees working at BioMarin Pharmaceutical
It is biomarin.com
BioMarin Pharmaceutical is in the Healthcare sector
BioMarin Pharmaceutical is in the Biotechnology industry
The following five companies are BioMarin Pharmaceutical's industry peers: